Abstract
Thiopurines are effective in maintaining remission in chronic inflammatory bowel diseases, but incomplete response or side effects are common during standard-dose treatment. In this article thiopurine metabolism and pharmacogenetic aspects are summarized showing their benefits in improving therapy in chronic inflammatory bowel disease. An increasing body of evidence suggests that a large part of the observed non-pancreatic side effects and poor responses can be solved by tailoring thiopurine therapy using measurement of thiopurine methyltransferase and metabolites and by using a combination therapy with low-dose thiopurines and allopurinol.
| Translated title of the contribution | Optimized thiopurine treatment in chronic inflammatory bowel disease. |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 176 |
| Issue number | 22 |
| Pages (from-to) | 2-5 |
| Number of pages | 4 |
| ISSN | 0041-5782 |
| Publication status | Published - 2014 |